Table 1.

Details of Individual Study

Study	Country	Study design	Therapy		Method	Time of therapy (weeks)	Dosage (mg/mg)	Main inclusion criteria	Outcome measures
			Experimental	Control
Bechara et al. (2008)	Argentina	RCT	Tamsulosin plus Tadalafil	Tamsulosin	Oral	6	0.4 mg + 20 mg/0.4 mg	Men ≥50 years old with a history of BPH, IPSS ≥12, PSA ≤4.0 ng/mL, Qmax >5 mL/s and <15 mL/s, MVV >125 mL	IPSS, QoL, VAS, GAQ, Qmax, PVR, IIEF
Regadas et al. (2013)	Brazil	RCT	Tamsulosin plus Tadalafil	Tamsulosin	Oral	4	0.4 mg + 5 mg/0.4 mg	Men ≥45 years old with a history of BPH/LUTS, BOOI ≥20, IPSS ≥14	IPSS, PdetQmax, Qmax
Singh et al. (2014)	India	RCT	Tamsulosin plus Tadalafil	Tamsulosin	Oral	12	0.4 mg + 10 mg/0.4 mg	Men ≥45 years old with a history of LUTS secondary to BPH, IPSS >8, PSA ≤4.0 ng/mL, Qmax >5 mL/s, and <15 mL/s, MVV >125 mL	IPSS, QoL, Qmax, PVR, IIEF
Karami et al. (2016)	Iran	RCT	Tamsulosin plus Tadalafil	Tamsulosin	Oral	12	0.4 mg + 20 mg/0.4 mg	Men ≥45 years old with a history of BPH/LUTS, total IPSS ≥12	PSA, PVR, IPSS, Qmax, IIEF
Negoro et al. (2020)	Japan	RCT	Tamsulosin plus Tadalafil	Tamsulosin	Oral	6	0.2 mg + 5 mg/0.2 mg	Men ≥50 years old with a history of BPE, PV ≥20 and ≤40 mL, total IPSS ≥8, QoL ≥3	QoL, PVR, IPSS, Qmax, IIEF
Nagasubramanian et al. (2020)	India	RCT	Tamsulosin plus Tadalafil	Tamsulosin	Oral	12	0.4 mg + 5 mg/0.4 mg	Men >45 years old with a history of LUTS, IPSS ≥8 and ≤19, Qmax ≥5 mL/s and ≤15 mL/s	IPSS, QoL, IIEF, Qmax, PVR

Note. RCT = randomized controlled trial; BPH = benign prostatic hyperplasia; IPSS = international prostatic symptoms score; PSA = prostatic-specific antigen; Qmax = maximum flow rate; MVV = minimum voided volume; QoL = quality of life; VAS = visual analogue scale; GAQ = global assessment quality; PVR = post-void residual volume; IIEF = International Index of Erectile Function; LUTS = lower urinary tract symptoms; BOOI = bladder outlet obstruction index; BPE = benign prostatic enlargement; PV = prostate volume.